Anti-PDCD1 / PD-1 / CD279 Reference Antibody (spartalizumab)
- Product Code: 140408
Molecular Weight: | Molecular Formula: | ||
---|---|---|---|
EC Number: | MDL Number: | ||
Melting Point: | Boiling Point: | ||
Density: | Storage Condition: | -20℃ |
Product Description:
Used in cancer immunotherapy to block the PD-1 receptor on T-cells, enhancing the immune system's ability to detect and destroy tumor cells. It is applied in treating various malignancies, including melanoma, non-small cell lung cancer, and other solid tumors. By inhibiting the PD-1 immune checkpoint pathway, it helps restore anti-tumor immune responses that cancer cells often suppress. Currently utilized in clinical trials and therapeutic regimens, often in combination with other immunotherapies or treatments like chemotherapy and radiation.
Sizes / Availability / Pricing:
Size | Availability | Price | Quantity |
---|---|---|---|
50μg | 10-20 days | €131.99 |
+
-
|
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (spartalizumab)
Used in cancer immunotherapy to block the PD-1 receptor on T-cells, enhancing the immune system's ability to detect and destroy tumor cells. It is applied in treating various malignancies, including melanoma, non-small cell lung cancer, and other solid tumors. By inhibiting the PD-1 immune checkpoint pathway, it helps restore anti-tumor immune responses that cancer cells often suppress. Currently utilized in clinical trials and therapeutic regimens, often in combination with other immunotherapies or treatments like chemotherapy and radiation.
Mechanism | - |
Appearance | - |
Longevity | - |
Strength | - |
Storage | - |
Shelf Life | - |
Allergen(s) | - |
Dosage (Range) | - |
Recommended Dosage | - |
Dosage (Per Day) | - |
Recommended Dosage (Per Day) | - |
Mix Method | - |
Heat Resistance | - |
Stable in pH range | - |
Solubility | - |
Product Types | - |
INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
€0.00
€0.00
Total :